CN103954766A - 转铁蛋白受体检测试剂盒及制备方法 - Google Patents
转铁蛋白受体检测试剂盒及制备方法 Download PDFInfo
- Publication number
- CN103954766A CN103954766A CN201410035490.9A CN201410035490A CN103954766A CN 103954766 A CN103954766 A CN 103954766A CN 201410035490 A CN201410035490 A CN 201410035490A CN 103954766 A CN103954766 A CN 103954766A
- Authority
- CN
- China
- Prior art keywords
- reagent
- tfr
- antibody
- solution
- latex microsphere
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title claims abstract description 63
- 239000002245 particle Substances 0.000 claims abstract description 109
- 239000004816 latex Substances 0.000 claims abstract description 100
- 229920000126 latex Polymers 0.000 claims abstract description 100
- 239000004005 microsphere Substances 0.000 claims abstract description 84
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 71
- 238000000034 method Methods 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000004094 surface-active agent Substances 0.000 claims abstract description 16
- 239000000375 suspending agent Substances 0.000 claims abstract description 14
- 239000000243 solution Substances 0.000 claims description 103
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 51
- 239000008363 phosphate buffer Substances 0.000 claims description 51
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 45
- 238000006243 chemical reaction Methods 0.000 claims description 25
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 24
- 230000002421 anti-septic effect Effects 0.000 claims description 21
- 238000013016 damping Methods 0.000 claims description 19
- 239000012530 fluid Substances 0.000 claims description 19
- 238000005406 washing Methods 0.000 claims description 19
- 229910019142 PO4 Inorganic materials 0.000 claims description 18
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 18
- 239000010452 phosphate Substances 0.000 claims description 18
- 238000001556 precipitation Methods 0.000 claims description 18
- 239000003352 sequestering agent Substances 0.000 claims description 13
- 239000008367 deionised water Substances 0.000 claims description 12
- 229910021641 deionized water Inorganic materials 0.000 claims description 12
- 238000010790 dilution Methods 0.000 claims description 11
- 239000012895 dilution Substances 0.000 claims description 11
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 9
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000008366 buffered solution Substances 0.000 claims description 8
- 230000008878 coupling Effects 0.000 claims description 7
- 238000010168 coupling process Methods 0.000 claims description 7
- 238000005859 coupling reaction Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- -1 antiseptic Substances 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 239000006172 buffering agent Substances 0.000 claims description 4
- 230000009514 concussion Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 108010033576 Transferrin Receptors Proteins 0.000 abstract description 6
- 125000003277 amino group Chemical group 0.000 abstract description 4
- 102000005962 receptors Human genes 0.000 abstract description 4
- 108020003175 receptors Proteins 0.000 abstract description 4
- 230000001965 increasing effect Effects 0.000 abstract description 3
- 102000007238 Transferrin Receptors Human genes 0.000 abstract 3
- 239000012581 transferrin Substances 0.000 abstract 3
- 238000010382 chemical cross-linking Methods 0.000 abstract 2
- 239000003755 preservative agent Substances 0.000 abstract 2
- 230000002335 preservative effect Effects 0.000 abstract 2
- 239000002738 chelating agent Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 30
- 229910052742 iron Inorganic materials 0.000 description 15
- 239000000523 sample Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 238000004321 preservation Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 description 5
- 101710188974 Fatty acid-binding protein, liver Proteins 0.000 description 5
- 101710189565 Fatty acid-binding protein, liver-type Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000008857 Ferritin Human genes 0.000 description 3
- 108050000784 Ferritin Proteins 0.000 description 3
- 238000008416 Ferritin Methods 0.000 description 3
- 102000002070 Transferrins Human genes 0.000 description 3
- 108010015865 Transferrins Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 239000003547 immunosorbent Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000000267 erythroid cell Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 150000001455 metallic ions Chemical class 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000004879 turbidimetry Methods 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010017480 Hemosiderin Proteins 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/723—Glycosylated haemoglobin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
测试序号 | 实施例1 | 实施例2 | 实施例3 |
1 | 9.9 | 9.9 | 9.5 |
2 | 9.6 | 9.8 | 9.6 |
3 | 10.4 | 9.9 | 10.5 |
4 | 10.2 | 10.0 | 10.5 |
5 | 9.7 | 10.1 | 9.3 |
6 | 10.3 | 10.2 | 9.9 |
7 | 9.5 | 10.1 | 9.7 |
8 | 10.8 | 10.2 | 10.2 |
9 | 10.7 | 9.9 | 10.1 |
10 | 10.0 | 10.1 | 10.5 |
平均值(M) | 10.11 | 10.02 | 9.98 |
标准差(S) | 0.45 | 0.14 | 0.45 |
变异系数(CV%) | 4.45% | 1.40% | 4.51% |
相对偏差(Bias%) | 1.10% | 0.20% | 0.20% |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410035490.9A CN103954766B (zh) | 2014-01-24 | 2014-01-24 | 转铁蛋白受体检测试剂盒及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410035490.9A CN103954766B (zh) | 2014-01-24 | 2014-01-24 | 转铁蛋白受体检测试剂盒及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103954766A true CN103954766A (zh) | 2014-07-30 |
CN103954766B CN103954766B (zh) | 2015-07-15 |
Family
ID=51332064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410035490.9A Active CN103954766B (zh) | 2014-01-24 | 2014-01-24 | 转铁蛋白受体检测试剂盒及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103954766B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110736735A (zh) * | 2018-07-18 | 2020-01-31 | 博阳生物科技(上海)有限公司 | 一种均相化学发光检测试剂盒及其应用 |
CN111157740A (zh) * | 2019-12-28 | 2020-05-15 | 王贤俊 | 一种iv型胶原蛋白的检测试剂盒及其制备方法 |
CN111308087A (zh) * | 2020-02-21 | 2020-06-19 | 安徽大千生物工程有限公司 | 一种用于检测可溶性转铁蛋白受体sTfR的测定试剂盒及其制备使用方法 |
CN112409487A (zh) * | 2020-11-27 | 2021-02-26 | 宁波赛珀生物技术有限公司 | 抗可溶性转铁蛋白受体抗体及其应用 |
CN113125711A (zh) * | 2019-12-31 | 2021-07-16 | 博阳生物科技(上海)有限公司 | 一种受体试剂及其应用 |
CN114047338A (zh) * | 2021-11-10 | 2022-02-15 | 上海捷门生物技术有限公司 | 一种尿液转铁蛋白检测试剂盒及其检测方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102621330A (zh) * | 2012-04-05 | 2012-08-01 | 中国疾病预防控制中心营养与食品安全所 | 用于检测人体铁储量的蛋白芯片及其试剂盒 |
EP1909106B1 (en) * | 2001-09-14 | 2013-01-02 | F. Hoffmann-La Roche AG | Differential diagnosis of disorders of iron metabolism by means of four parameters and recommendations for the treatment of these disorders of iron metabolism |
CN103513038A (zh) * | 2013-05-16 | 2014-01-15 | 武汉生之源生物科技有限公司 | 半乳糖凝集素3检测试剂盒及制备方法 |
-
2014
- 2014-01-24 CN CN201410035490.9A patent/CN103954766B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1909106B1 (en) * | 2001-09-14 | 2013-01-02 | F. Hoffmann-La Roche AG | Differential diagnosis of disorders of iron metabolism by means of four parameters and recommendations for the treatment of these disorders of iron metabolism |
CN102621330A (zh) * | 2012-04-05 | 2012-08-01 | 中国疾病预防控制中心营养与食品安全所 | 用于检测人体铁储量的蛋白芯片及其试剂盒 |
CN103513038A (zh) * | 2013-05-16 | 2014-01-15 | 武汉生之源生物科技有限公司 | 半乳糖凝集素3检测试剂盒及制备方法 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110736735A (zh) * | 2018-07-18 | 2020-01-31 | 博阳生物科技(上海)有限公司 | 一种均相化学发光检测试剂盒及其应用 |
CN111157740A (zh) * | 2019-12-28 | 2020-05-15 | 王贤俊 | 一种iv型胶原蛋白的检测试剂盒及其制备方法 |
CN113125711A (zh) * | 2019-12-31 | 2021-07-16 | 博阳生物科技(上海)有限公司 | 一种受体试剂及其应用 |
CN113125711B (zh) * | 2019-12-31 | 2023-07-28 | 科美博阳诊断技术(上海)有限公司 | 一种受体试剂及其应用 |
CN111308087A (zh) * | 2020-02-21 | 2020-06-19 | 安徽大千生物工程有限公司 | 一种用于检测可溶性转铁蛋白受体sTfR的测定试剂盒及其制备使用方法 |
CN112409487A (zh) * | 2020-11-27 | 2021-02-26 | 宁波赛珀生物技术有限公司 | 抗可溶性转铁蛋白受体抗体及其应用 |
CN112409487B (zh) * | 2020-11-27 | 2022-04-29 | 宁波赛珀生物技术有限公司 | 抗可溶性转铁蛋白受体抗体及其应用 |
CN114047338A (zh) * | 2021-11-10 | 2022-02-15 | 上海捷门生物技术有限公司 | 一种尿液转铁蛋白检测试剂盒及其检测方法 |
CN114047338B (zh) * | 2021-11-10 | 2024-03-12 | 上海捷门生物技术有限公司 | 一种尿液转铁蛋白检测试剂盒及其检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103954766B (zh) | 2015-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103954766B (zh) | 转铁蛋白受体检测试剂盒及制备方法 | |
CN102759631B (zh) | 一种定量检测降钙素原pct的胶乳增强免疫比浊试剂盒 | |
CN103389381B (zh) | 附睾蛋白4化学发光检测试剂盒及其制备方法 | |
CN101699287B (zh) | 匀相溶胶颗粒型胱抑素c测定试剂盒及其制备方法 | |
CN103954776B (zh) | Ngal光激发化学发光检测试剂盒、其制备及使用方法 | |
CN103823070A (zh) | 一种高灵敏度的胱抑素c测定试剂盒 | |
CN109725160B (zh) | 一种降钙素原(pct)检测试剂盒 | |
CN110514848A (zh) | 一种糖化血红蛋白抗体复合物和糖化血红蛋白检测试剂盒 | |
CN111044724B (zh) | 一种胸苷激酶1磁微粒化学发光测定试剂盒及其制备方法 | |
CN103123319A (zh) | 心型脂肪酸结合蛋白含量检测试剂盒及其制备方法 | |
CN108872590A (zh) | 可同时检测血清和尿液样本中β2-微球蛋白的试剂盒 | |
CN108051439A (zh) | 一种单试剂肝素结合蛋白检测试剂盒及其制备方法 | |
CN103645323A (zh) | 一种胱抑素c检测试剂盒及其制备方法 | |
CN112014577B (zh) | 一种提高gpc3检测灵敏度的试剂盒及其制备方法 | |
CN105548547A (zh) | 基于流式细胞仪的检测肺癌标志物的流式阵列免疫分析试剂盒 | |
CN103323596A (zh) | 髓过氧化物酶含量检测试剂盒及其制备方法 | |
CN202916286U (zh) | 一种定量检测降钙素原pct的胶乳增强免疫比浊试剂盒 | |
CN108872616A (zh) | 基于单粒径胶乳颗粒的检测ngal的免疫胶乳比浊法试剂盒 | |
CN102809654A (zh) | 一种双粒子复合的c-反应蛋白检测试剂盒 | |
CN101957369A (zh) | 用于免疫测定的增强标记缀合物 | |
CN101846684A (zh) | 检测aib1的双抗体夹心酶联免疫吸附试剂盒及制备方法 | |
CN108593940B (zh) | 一种尿液转铁蛋白检测试剂盒 | |
CN103529225B (zh) | 一种肝型脂肪酸结合蛋白含量检测试剂盒及其制备方法 | |
CN109212189A (zh) | 一种定量检测血清、血浆中her-2蛋白含量的试剂盒 | |
CN109521200A (zh) | 一种同时检测血浆中多种成分含量的试剂盒、方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 430206 B11 building, No. 818, hi tech medical center, hi tech Avenue, East Lake Development Zone, Wuhan, Hubei, 2 Patentee after: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK CO., LTD. Address before: 430206 hi tech medical equipment Park No. 818, hi tech Avenue, East Lake Development Zone, Wuhan, Hubei, B11 Patentee before: Wuhan Life Origin Biotech Co., Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Transferring receptor detection kit and preparation method thereof Effective date of registration: 20180612 Granted publication date: 20150715 Pledgee: Wuhan rural commercial bank Limited by Share Ltd Optics Valley branch Pledgor: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK CO., LTD. Registration number: 2018420000024 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190620 Granted publication date: 20150715 Pledgee: Wuhan rural commercial bank Limited by Share Ltd Optics Valley branch Pledgor: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK CO., LTD. Registration number: 2018420000024 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Transferring receptor detection kit and preparation method thereof Effective date of registration: 20191107 Granted publication date: 20150715 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co., Ltd. Pledgor: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK CO., LTD. Registration number: Y2019420000025 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201223 Granted publication date: 20150715 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co.,Ltd. Pledgor: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK Co.,Ltd. Registration number: Y2019420000025 |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 430000 1 / F, 2 / F and 3 / F, B11, hi tech medical device Park, 818 Gaoxin Avenue, Donghu Development Zone, Wuhan, Hubei Province Patentee after: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK Co.,Ltd. Address before: 2 / F, B11, Gaoke medical instrument Park, 818 Gaoxin Avenue, Donghu Development Zone, Wuhan, Hubei 430206 Patentee before: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK Co.,Ltd. |